Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.061 USD 7.21% Market Closed
Market Cap: 16.2m USD

Intrinsic Value

The intrinsic value of one ADAP stock under the Base Case scenario is 1.367 USD. Compared to the current market price of 0.061 USD, Adaptimmune Therapeutics PLC is Undervalued by 96%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADAP Intrinsic Value
1.367 USD
Undervaluation 96%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare ADAP to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ADAP?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Adaptimmune Therapeutics PLC
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Adaptimmune Therapeutics PLC

Current Assets 78.1m
Cash & Short-Term Investments 26.1m
Receivables 28.9m
Other Current Assets 23.2m
Non-Current Assets 52.5m
PP&E 46.9m
Intangibles 3.8m
Other Non-Current Assets 1.8m
Efficiency

Free Cash Flow Analysis
Adaptimmune Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Adaptimmune Therapeutics PLC

Revenue
65.1m USD
Cost of Revenue
-44.4m USD
Gross Profit
20.7m USD
Operating Expenses
-166.2m USD
Operating Income
-145.5m USD
Other Expenses
-24.3m USD
Net Income
-169.8m USD
Fundamental Scores

ADAP Profitability Score
Profitability Due Diligence

Adaptimmune Therapeutics PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

22/100
Profitability
Score

Adaptimmune Therapeutics PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

ADAP Solvency Score
Solvency Due Diligence

Adaptimmune Therapeutics PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
35/100
Solvency
Score

Adaptimmune Therapeutics PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

Wall Street analysts forecast ADAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADAP is 0.357 USD with a low forecast of 0.091 USD and a high forecast of 0.525 USD.

Lowest
Price Target
0.091 USD
49% Upside
Average
Price Target
0.357 USD
485% Upside
Highest
Price Target
0.525 USD
761% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Adaptimmune Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for ADAP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ADAP Insider Trading
Buy and sell transactions by insiders